

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

Claim 1-13 (Canceled)

Claim 14 (Previously Presented) A method for prevention or treatment of atherosclerosis in a subject, comprising administering a therapeutically effective amount of a composition comprising one or more active components selected from the group consisting of oxidized low density lipoprotein (Ox LDL) and malondialdehyde LDL (MDA-LDL) and a pharmaceutically acceptable carrier for oral administration, wherein said administration is in a sufficient amount to induce production of IL-10 or TGF $\beta$  and to suppress IFN- $\gamma$ , thereby inhibiting at least one atherosclerosis-related symptom in said subject.

Claim 15-18 (Canceled)

Claim 19 (Previously Presented) The method according to claim 14, wherein said active component is oxidized low density lipoprotein (Ox LDL).

Claim 20-25 (Canceled)

Claim 26 (Withdrawn): The method according to claim 14, wherein said active component is malondialdehyde LDL (MDA-LDL).

Claim 27 (Previously Presented) A method for prevention or treatment of atherosclerosis in a subject, comprising administering a therapeutically effective amount of a composition consisting of modified low density lipoprotein and a pharmaceutically acceptable carrier for oral administration, wherein said administration is in a sufficient amount to induce production of IL-10 or TGF $\beta$  and to suppress IFN- $\gamma$ , thereby inhibiting at least one atherosclerosis-related symptom in said subject.

Claim 28 (Previously Presented) A method for prevention or treatment of atherosclerosis in a subject, comprising administering a therapeutically effective amount of a composition

Serial No. 09/806,400

Applicant(s): Schoenfeld *et al.*

comprising one or more active components selected from the group consisting of human modified low density lipoprotein and human oxidized low density lipoprotein and a pharmaceutically acceptable carrier for oral administration, wherein said administration is in a sufficient amount to induce production of IL-10 or TGF $\beta$  and to suppress IFN- $\gamma$ , thereby inhibiting at least one atherosclerosis-related symptom in said subject.